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1. INTRODUCTION 
Transplantation-associated thrombotic 
microangiopathy (TA-TMA) is a challenging 
complication following hematopoietic stem cell 
transplantation (HSCT). Patients  present with 
microangiopathic hemolytic anemia, defined de novo 
acute anemia and thrombocytopenia not explained by 
another process, elevated lactate dehydrogenase (LDH), 
excessive transfusion requirements, and shistocytosis in 
the blood. However, the signs and symptoms of TA-TMA 
can be confused with other common transplantation 
associated or malignancy associated complications, such 
as acute graft-versus-host disease (GVHD), infections, 
graft failure, immune-mediated thrombocytopenia, 
venoocclusive disease, relapse, medication induced side-
effects, such as hypertension or acute renal failure. 
Incidence rates of TA-TMA after HSCT are reported 
between 0.5 and 63.6%, this wide range is related to 
factors including the inability to obtain a tissue biopsy, the 
various and changing diagnostic criteria used to define 
TA-TMA, and the changes of conditioning regimens in the 
past years.   
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The pathogenesis of TA-TMA is related to 
endothelial injury, only partially explaining the systemic 
nature of this complication. Recent observations 
suggested that complement alternative pathway 
dysregulation may also be involved in the pathogenesis of 
TA-TMA. Excessive complement activation (as reflected 
by increased levels of anaphylatoxins C3a and C5a, and 
terminal pathway complement complex) are known to 
activate, among others, platelets, granulocytes, endothelial 
cellsand coagulation, leading to cellular injury and 
development of TA-TMA. Jodele et al. reported that 
evidence of terminal complement activation (elevated 
sC5b-9 levels) in the blood at the time of TMA diagnosis 
were associated with very poor survival. However, 
consecutive changes in complement profile and 
complement activation product levels, and their 
relationship to complications following HSCT, are 
scarcely known today.  
Based on the recent recognition of complement 
alternative pathway dysregulation after HSCT, and on the 
promising results of complement inhibition in various 
forms of TMA besides atypical hemolytic uremic 
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syndrome, eculizumab, a humanized monoclonal antibody 
against complement C5 was also evaluated in the setting 
of TA-TMA. Therefore, there is a demanding clinical need 
to recognize, or to predict TA-TMA as early as possible, 
but current possibilities to achieve these goals are largely 
limited. The diagnostic criteria used for TA-TMA 
recognition include hematologic and renal injury markers, 
reflecting the presence of already ongoing, clinically 
manifest organ damages. The recent modification of 
diagnostic criteria that included markers of complement 
activation, proteinuria, and hypertension, led to an 
improved and earlier detection of the developing clinical 
TA-TMA. However, to the best of our knowledge, there 
are only a few studies that investigated the potential role 
of the biomarkers for TA-TMA in the post-HSCT setting, 
such as soluble adhesion molecule-, serum neutrophil 
extracellular trap- and complement activation product 
levels.  
Based on the recent diagnostic criteria for TA-
TMA, and the description of alternative pathway 
dysregulation in TA-TMA patients, on the high risk of 
developing TMA in patients with elevated terminal 
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pathway activation marker levels, and on the first 
promising results with anti-C5 complement inhibition in 
TA-TMA, we decided to focus on potential predictive 
complement biomarkers in the post-HSCT setting. 
 
2. AIMS 
The aims of the work presented in this thesis are: 
 
1) To identify patients with TA-TMA using five different 
diagnostic TA-TMA criteria published in literature and to 
compare the various groups for TA-TMA parameters. 
 
2) To analyze longitudinal changes of complement profile 
after HSCT in a prospective, consecutive pediatric cohort. 
 
3) To identify potential complement biomarkers of TA-
TMA development. 
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3. METHODS 
Patient Population, Sample, and Data Collection 
Forty pediatric patients underwent allogeneic stem cell 
transplantation for malignant (n=20) and non-malignant 
(n=20) indications at our center in Budapest from 
November 2013 to June 2015. Thirty-three of the 40 
patients fulfilled inclusion criteria and were included in 
further data evaluation and complement measurements. 
Exclusion criterias in this prospective cohort were weight 
below 10 kg (5 patients were excluded) and early death 
(<30 days after transplantation, 2 patients were excluded). 
Samples were systematically collected before 
transplantation, representing baseline level, and on day 28, 
56 and 100 after HSCT. Blood sampling followed the 
predefined protocol, and no extra samples were taken, if a 
transplantation related complication occurred.  
Informed consent was obtained in accordance with the 
Declaration of Helsinki and the study was approved by the 
institutional Ethics Committee on Human Research. 
  
6 
 
Determination of Complement and Other Laboratory 
and Clinical Parameters 
Complement pathway activities, components, activation 
product levels, solubile terminal pathway activation 
marker (sC5b-9) levels and ADAMTS13 activity were 
systematically measured before transplantation and on day 
28, 56 and 100 after HSCT. The following TMA activity 
markers were registered: serum LDH, creatinine and 
haptoglobin levels, new onset anemia, thrombocytopenia, 
fragmentocytes (determined by automated hematology 
analyzer), Coombs test, proteinuria and hypertension. 
Definition of Transplant-Related Complications 
Graft versus host disease (GVHD) was diagnosed using 
Glucksberg criteria, viral reactivation (Epstein-Bar virus, 
cytomegalovirus, adenovirus) was monitored. Five sets of 
diagnostic criteria were used to define TA-TMA: 1) the 
diagnostic criteria of Blood and Marrow Transplant 
Clinical Trials Network Toxicity Committee Consensus 
Summary (BMT CTN),  2) the clinical criteria of the 
International Working Group (IWG), 3) the diagnostic 
criteria proposed by Cho at al.,  4) the diagnostic criteria 
of City of Hope, and 5) the diagnostic criteria proposed by 
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Jodele et al.. The date of diagnosis was defined as the date 
when all of the TA-TMA diagnostic criteria proposed by 
Jodele et al. were fulfilled. 
Statistical Methods 
Because most of the continuous variables showed 
skewed distribution, data are presented as median (range 
or interquartile range) and nonparametric tests were used 
for group comparisons. The Kaplan-Meier method was 
used for estimating TA-TMA event- free survival and the 
log-rank test was used to compare survival curves. Two-
sided p- values were calculated and p< 0.05 was 
considered statistically significant. Analyses were 
performed using the Statistica 8.0 and the GraphPad Prism 
6.03 statistical software. 
 
4. RESULTS 
Study Cohort Demographics 
Thirty- three consecutive pediatric patients (9.6 ± 
4.4 years old) were included in this study who underwent 
allogeneic HSCT due to malignant (n=17) or non 
malignant (n=16) indications. Overall, 24 of 33 (73%) 
patient received treosulfan-based conditioning regimen 
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for malignant and non-malignant disorders. The main stem 
cell source was bone marrow (70%) from matched 
unrelated donors (76%). Viral reactivation was detected in 
15 of 33 patients and was the most common transplant-
related complication in our study population. In addition, 
1 patient had primary CMV infection and 1 patient had 
primary EBV infection. Eleven (33%) patients 
experienced grade I or II acute GVHD. 
Diagnosis of TA-TMA 
Considering the five different diagnostic systems 2 
of 33 subject met the BMT CTN , 7 of 33 the IWG criteria, 
7 of 33 the diagnostic criteria of Cho et al., 3 of 33 the 
diagnostic criteria of City of Hope, and 10 of 33 patients 
met the diagnostic criteria for TA-TMA proposed by 
Jodele et al.. Altogether, incidence of TA-TMA was 
observed in the range of 6% (2 of 33) to 30% (10 of 33) 
depending on the diagnostic criteria applied. Seven out of 
the 10 patients with TA-TMA fulfilled at least 3 TA-TMA 
criteria of the various diagnostic systems. All patients met 
the diagnostic criteria for TA-TMA proposed by Jodele et 
al., who met any of the other four diagnostic criteria. Three 
patients had normal haptoglobin level and normal kidney 
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function (no doubling of serum creatinine) during the 
whole transplantation period and would be defined as TA-
TMA only according to Jodele et al. and/ or City of Hope. 
Surprisingly, grade I to II GVHD had almost the same 
incidence as TA-TMA after reduced toxicity conditioning 
regimen in our cohort. 
Clinical Characteristics of Patients with TA-TMA 
To include every patient with TA-TMA, we used 
all available diagnostic criteria, and altogether 10 of 33 
patients were defined as TA-TMA from mild to severe 
cases for further data evaluation. TA-TMA occurred 
typically after GVHD and/or viral infection or 
reactivation. TA-TMA was preceded by acute GVHD in 3 
of 10, by viral reactivation in 2 of 10, or by both in 4 of 10 
cases. After reduced toxicity conditioning regimen, in 
majority of patients TA-TMA was a mild, self-limiting 
form, without any sign of organ damage, and resolved 
after the withdrawal or change of calcineurin inhibitor.  
Longitudinal Analysis of Complement Activation 
During the First 100 Days after HSCT 
Complement terminal pathway activation complex 
sC5b-9 level was the only parameter that showed 
10 
 
significant changes of the measured complement 
parameters. A clear and significant association with TA-
TMA was observed, with peak sC5b-9 levels on day 28 in 
the TA-TMA group. Baseline sC5b-9 levels did not differ 
in patients without (200 (144-266) ng/mL, median 
(interquartile range)), or with (208 (166- 271) ng/mL) 
subsequent TA-TMA. However on day 28, patients who 
later developed TA-TMA had sC5b-9 concentrations of 
411 ng/mL (337-472, median, interquartile range), 
whereas patients without TA-TMA had 201 (185-290, 
p<0.05).  
Importantly, 10 of 10 patients with later TA-TMA 
showed an early increase of sC5b-9. There was no 
significant association of TA-TMA with changes in 
classical and alternative pathway activities, C3, C4, C4d, 
and C3a concentrations, and ADAMTS13 activity. 
Next, we analyzed the relationship between early 
increase of sC5b-9 and engraftment and additional 
transplantation related complications. Patients were 
stratified according to changes between baseline and day 
28 sC5b-9 levels, and TA-TMA showed a clear and 
remarkable association with early increase of terminal 
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pathway activation. Ten patients of 19, who had an early 
increase in sC5b-9, developed later TA-TMA, whereas 
none of the 14 patients without an increase of sC5b-9 
developed TA-TMA (p=0.001). 
Hypertension until day 28 was the only TMA 
activity marker that was significantly associated with early 
increase of sC5b-9 levels (p=0.027), whereas presence of 
decreased haptoglobin concentrations showed a tendency 
for association (p=0.098). 
Finally, we analyzed if early increase of sC5b-9 
levels may help clinical management of HSCT patients 
and calculated sensitivity and specificity values to predict 
development of TA-TMA. Increase in sC5b-9 
concentration had 100% sensitivity and 61% specificity 
for TA-TMA in our pediatric cohort. 
Patient Survival 
Overall survival after a median 2.6 (interquartile 
range, 1.5-2.9) year follow-up time was 24 of 33 (73%). 
Overall survival was 15 of 16 (94%) in nonmalignant 
patients. Accordingly, in patients with malignancy and 
with treosulfan- based myeloablative regimen, relapse rate 
was high, 7 of 17 patients died of relapse, and 1 of 17 
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patient in transplant-related mortality (TRM). TRM rate 
was low (2 of 33; 6%) after day 30. Seven of 10 patients 
(70%) with TA-TMA survived, compared with 17 of 23 
(74%) patients without TA-TMA. Furthermore, early 
elevation of sC5b-9 showed no association with mortality. 
 
5. CONCLUSIONS 
The aim of my dissertation was to provide 
observational data about the incidence of TA-TMA in our 
pediatric cohort with different diagnostic criteria, to 
observe the complement biomarker changes after HSCT, 
and to investigate the possible link between the 
development of TA-TMA and complement activation. 
Our results demonstrate a remarkably strong association 
between the presence of an early increase of terminal 
complement pathway activation and later development of 
TA-TMA, translating to 100% sensitivity to predict the 
occurrence of this complication.  
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The conclusions of the dissertation are 
summerized below: 
 
(1) Based on our observations, thrombotic 
microangiopathy is a frequent complication of 
hematopoietic stem cell transplantation. Incidence of TA-
TMA was observed in the range of 6% (2 of 33) to 30% 
(10 of 33) depending on the diagnostic criteria applied. 
Altogether, we identified 10 of 33 patients, from mild to 
severe TA-TMA cases in our pediatric cohort. TA-TMA 
was diagnosed typically on day 61 (range, 16-98) after 
HSCT. Incidence of TA-TMA and time of diagnosis is 
influenced by the diagnostic criteria used. 
 
(2) TA-TMA occurred typically after GVHD 
and/or viral infection or reactivation. TA-TMA was 
preceded by acute GVHD in 3 of 10, by viral reactivation 
in 2 of 10, or by both in 4 of 10 cases. After reduced 
toxicity conditioning regimen, in majority of patients TA-
TMA was a mild, self-limiting form, without any sign of 
organ damage, and resolved after the withdrawal or 
change of calcineurin inhibitor.  
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(3) Complement terminal pathway activation 
complex sC5b-9 level was the only parameter that showed 
significant changes of the measured complement 
parameters. There was no significant association of TA-
TMA with changes in classical and alternative pathway 
activities, C3, C4, C4d, and C3a concentrations, and 
ADAMTS13 activity. 
 
 
(4) We report results of the first consecutive, 
longitudinal study on complement activation during the 
first 100 days after HSCT, and describe the remarkable 
close association between early increase of terminal 
pathway activation marker levels and later development of 
TA-TMA. We found that early (i.e. from baseline to day 
28) increase of sC5b-9, before the development of most of 
the complications, can predict later TA-TMA. Increase in 
sC5b-9 concentration had 100% sensitivity and 61% 
specificity for TA-TMA in our pediatric cohort. Baseline 
sC5b-9 levels did not differ in patients without  (200 (144-
266) ng/mL, median (interquartile range)), or with (208 
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(166- 271) ng/mL) subsequent TA-TMA, however, on day 
28 significant differences were observed (201 (185-290) 
ng/mL versus 411 (337-471) ng/mL, p=0.004). 
Importantly, all 10 patients with TMA showed increase in 
sC5b-9 level from baseline level to day 28, whereas in 
patients without TMA the same tendency was observed for 
only 9/23 (p=0.031). 
 
(5) Due to the high proportion of treosulfan-
based conditioning regimens (24 of 33) in our cohort the 
rate of significant early transplantation- related 
complications was reasonably low, and nonrelapse 
mortality did not associate with TA-TMA. If our 
observations can be validated in an independent cohort 
with more aggressive or toxic conditioning regimens, the 
measurement of complement activation marker sC5b-9 
may be useful, in order to identify patients with early 
increase of sC5b-9, as a sign of increased risk of 
developing later TA-TMA. Early monitoring of 
complement activation marker sC5b-9 and activity 
markers of TA-TMA would guide physicians to facilitate 
subsequent therapy decisions, on time. Further studies 
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enrolling higher number of patients are necessary to 
determine if terminal pathway activation is an independent 
predictor of TMA development after HSCT.  
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